stoxline Quote Chart Rank Option Currency Glossary
  
Paragon 28, Inc. (FNA)
13.06  -0.03 (-0.23%)    02-11 16:19
Open: 13.07
High: 13.075
Volume: 334,767
  
Pre. Close: 13.09
Low: 13.05
Market Cap: 1,093(M)
Technical analysis
2025-02-11 4:45:32 PM
Short term     
Mid term     
Targets 6-month :  15.33 1-year :  17.91
Resists First :  13.13 Second :  15.33
Pivot price 12.59
Supports First :  10.84 Second :  9.43
MAs MA(5) :  13.03 MA(20) :  12.11
MA(100) :  8.93 MA(250) :  8.87
MACD MACD :  0.7 Signal :  0.6
%K %D K(14,3) :  96.8 D(3) :  96.4
RSI RSI(14): 77.7
52-week High :  14.77 Low :  4.65
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ FNA ] has closed below upper band by 31.0%. Bollinger Bands are 7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.09 - 13.16 13.16 - 13.22
Low: 12.88 - 12.96 12.96 - 13.03
Close: 12.93 - 13.06 13.06 - 13.18
Company Description

Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Headline News

Tue, 11 Feb 2025
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider

Mon, 10 Feb 2025
Paragon 28, Inc. (FNA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Mon, 10 Feb 2025
Grabar Law Office is Investigating Claims on Behalf of - GlobeNewswire

Thu, 30 Jan 2025
Strength Seen in Paragon 28, Inc. (FNA): Can Its 8.3% Jump Turn into More Strength? - Yahoo Finance

Wed, 29 Jan 2025
Zimmer Biomet to buy Paragon 28 for $1.2B - Mass Device

Wed, 29 Jan 2025
Zimmer Biomet Snaps Up Paragon 28 In $1.2 Billion Deal: Details - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 84 (M)
Shares Float 40 (M)
Held by Insiders 40.5 (%)
Held by Institutions 60.7 (%)
Shares Short 3,730 (K)
Shares Short P.Month 3,550 (K)
Stock Financials
EPS -0.68
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.66
Profit Margin -23 %
Operating Margin -13.6 %
Return on Assets (ttm) -8.4 %
Return on Equity (ttm) -33.8 %
Qtrly Rev. Growth 18.1 %
Gross Profit (p.s.) 2.26
Sales Per Share 2.92
EBITDA (p.s.) -0.26
Qtrly Earnings Growth 0 %
Operating Cash Flow -40 (M)
Levered Free Cash Flow -29 (M)
Stock Valuations
PE Ratio -19.5
PEG Ratio 0
Price to Book value 7.82
Price to Sales 4.47
Price to Cash Flow -27.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android